Chinook Therapeutics Announces Promotions of Tom Frohlich to Chief Operating Officer and Andrew King, D.V.M, Ph.D., to Chief ...
June 09 2021 - 8:15AM
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of precision medicines for kidney diseases, today
announced that Tom Frohlich, chief business officer, has been
promoted to chief operating officer (COO) of Chinook and Andrew
King, D.V.M, Ph.D., head of renal discovery and translational
medicine, has been promoted to chief scientific officer (CSO) of
Chinook.
“We are thrilled to announce these extremely well-deserved
promotions for both Tom and Andrew to recognize the important roles
they are playing in building Chinook into a leading kidney disease
company,” said Eric Dobmeier, president and chief executive officer
of Chinook Therapeutics. “Tom is a seasoned commercial and business
development executive who co-founded Chinook, led business
negotiations with AbbVie for our license to atrasentan and our
merger with Aduro, and has assumed broad operational
responsibilities at the company. Andrew is a highly-respected
expert in kidney disease biology who was instrumental in bringing
both atrasentan and BION-1301 into our pipeline and leads a
top-notch discovery, research and translational medicine team at
Chinook focused on advancing our pipeline of novel, precision
medicines for kidney disease.”
In his role as COO, Tom will oversee Chinook’s business
development, CMC, quality, new product planning, program management
and program team leadership functions. Tom co-founded and joined
Chinook in January 2019 as chief business officer. Prior to
Chinook, he served as entrepreneur-in-residence at Versant
Ventures. From 2014 to 2018, Tom was VP of business development at
Arbutus Biopharma, where he played a key role in multiple
transactions including a licensing deal with Alexion and the merger
of Tekmira/Oncore. Prior to that, Tom spent over 12 years working
internationally at J&J and Merck in various roles leading
commercial strategy across all stages of product development,
including the global launches of telaprevir and Stelara. Tom has a
B.Sc. in biochemistry from the University of Victoria and an MBA
from the University of Oxford.
In his role as CSO, Andrew will oversee the discovery research,
non-clinical development and translational medicine teams. Andrew
joined Chinook in May 2019 as head of renal discovery and
translational medicine. Prior to joining Chinook, Andrew was senior
director of discovery and translational biology at Ardelyx, where
he and his teams played key roles in delivering small molecule
candidates for the treatment of cardio-renal diseases, as well as
elucidating the novel molecular mechanism of action of tenapanor,
currently under NDA review by the FDA for the treatment of
hyperphosphatemia in dialysis patients. Previously, Andrew spent
over seven years at AbbVie in roles of increasing responsibility
and led the renal discovery scientific strategy to treat chronic
kidney disease. Andrew received his Ph.D. in pharmacology from
Michigan State University and completed training in Veterinary
Medicine and Surgery at Murdoch University in Australia.
About Chinook Therapeutics, Inc.Chinook
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing precision medicines for kidney diseases. Chinook’s
product candidates are being investigated in rare, severe chronic
kidney disorders with opportunities for well-defined clinical
pathways. Chinook’s lead program is atrasentan, a phase 3
endothelin receptor antagonist for the treatment of IgA nephropathy
and other proteinuric glomerular diseases. BION-1301, an anti-APRIL
monoclonal antibody is being evaluated in a phase 1b trial for IgA
nephropathy. In addition, Chinook is advancing CHK-336, an oral
small molecule LDHA inhibitor for the treatment of primary
hyperoxaluria, as well as research programs for other rare, severe
chronic kidney diseases. Chinook is building its pipeline by
leveraging insights in kidney single cell RNA sequencing,
human-derived organoids and new translational models, to discover
and develop therapeutics with differentiating mechanisms of action
against key kidney disease pathways. To learn more, visit
www.chinooktx.com.
Contact:Noopur LiffickVice President, Investor
Relations & Corporate Communicationsinvestors@chinooktx.com
media@chinooktx.com
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Sep 2023 to Sep 2024